Proteostasis

Proteostasis
Name	Proteostasis
Field	Molecular biology, Biochemistry
Notable people	Sydney Brenner, Lasker Award
Institutions	Max Planck Society, National Institutes of Health

Proteostasis Proteostasis is the regulated maintenance of the cellular protein complement that ensures proper folding, trafficking, function, and degradation. It integrates chaperone networks, quality-control pathways, and degradation systems to preserve proteome integrity throughout life and in response to stress. Research on proteostasis connects findings from laboratories such as the Laboratory of Molecular Biology, clinical work at the Mayo Clinic, and programs within the National Institutes of Health and European Molecular Biology Laboratory.

Overview

Proteostasis encompasses synthesis, folding, modification, localization, and disposal of proteins via coordinated actions of molecular chaperones, proteolytic systems, and signaling networks. Historical advances emerged from studies by Frederick Sanger on protein sequencing, genetic work by Sydney Brenner and Francis Crick on gene–protein relationships, structural insights from Max Perutz and John Kendrew, and cellular quality-control discoveries at institutions like the Max Planck Society and Cold Spring Harbor Laboratory. Contemporary efforts span collaborations involving the Howard Hughes Medical Institute, pharmaceutical companies such as Pfizer and Roche, and consortia funded by the Wellcome Trust.

Molecular Mechanisms of Proteostasis

Molecular mechanisms rely on conserved machineries including heat shock proteins (Hsp70, Hsp90), AAA+ ATPases, ubiquitin-conjugating enzymes, and proteasomes. Seminal biochemical studies at the Salk Institute and structural work at the European Synchrotron Radiation Facility revealed chaperone cycles and ATPase-driven unfolding fundamental to proteostasis. Protein ubiquitination was elucidated in laboratories associated with the University of Cambridge and the University of California, San Francisco, while autophagy-related conjugation systems were characterized by groups at the University of Tokyo and the Weizmann Institute of Science.

Cellular Pathways and Machinery

Key cellular pathways include the ubiquitin–proteasome system, autophagy–lysosome pathway, endoplasmic reticulum-associated degradation, and mitochondrial quality-control mechanisms. Research linking endoplasmic reticulum stress responses to disease involved investigators at the University of Pennsylvania and the Cold Spring Harbor Laboratory, while mitochondrial proteostasis studies drew on work from the National Institutes of Health and the Wistar Institute. Organelle-specific factors were identified through genetic screens in model organisms maintained at centers such as the European Molecular Biology Laboratory and the Max Planck Institute for Biology.

Proteostasis in Development and Aging

Proteostasis capacity is dynamic during development and declines with age, with implications shown by developmental genetics from Harvard Medical School and aging research at the Buck Institute for Research on Aging. Model-organism studies by groups at the University of Cambridge and Princeton University demonstrated links between proteostasis network activity, lifespan modulation, and stress resistance. Epidemiological and translational programs at institutions like the Mayo Clinic and Johns Hopkins University explore how age-related proteostasis decline contributes to organismal senescence and functional deterioration.

Dysregulation and Disease Associations

Proteostasis collapse underlies many disorders including neurodegenerative diseases (e.g., Alzheimer disease, Parkinson disease), myopathies, and certain cancers. Key discoveries came from collaborative efforts involving the Alzheimer's Association, clinical centers at Massachusetts General Hospital, and research consortia connecting the National Institutes of Health and the European Commission. Mutations in ubiquitin ligases, chaperones, or autophagy genes identified at laboratories such as Cold Spring Harbor Laboratory and University of California, Berkeley have been linked to inherited proteostasis disorders, while oncology studies at institutions like MD Anderson Cancer Center implicate proteostasis reprogramming in tumor progression.

Experimental Methods and Model Systems

Experimental approaches include genetic screens in Saccharomyces cerevisiae and Caenorhabditis elegans, biochemical assays developed at the Salk Institute and Max Planck Institute, structural biology at the European Synchrotron Radiation Facility and Brookhaven National Laboratory, and high-throughput proteomics at facilities like the European Bioinformatics Institute. Model systems from the Jackson Laboratory and imaging platforms at Stanford University enable in vivo monitoring of chaperone dynamics, aggregation, and degradation. Clinical studies coordinated by centers such as Mayo Clinic and UCSF Medical Center translate bench findings into patient-relevant biomarkers and outcome measures.

Therapeutic Strategies and Interventions

Therapeutic efforts target chaperone modulation, proteasome inhibitors, autophagy enhancers, and small molecules that stabilize folding intermediates. Drug discovery programs from Pfizer, Novartis, and academic spin-outs from Harvard University and MIT pursue modulators of Hsp90, proteasome activity, and selective autophagy pathways. Clinical trials coordinated by the National Institutes of Health and regulatory review by the Food and Drug Administration evaluate interventions for neurodegeneration, cancer, and inherited proteostasis disorders, while precision-medicine initiatives at the Broad Institute aim to match proteostasis-directed therapies to genetic and biomarker-defined patient subsets.

Category:Cellular processes